Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers

Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse. Using a transcriptome-powered targeted proteomics screen, we discovered a gene regulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Emadali, Anouk, Rousseaux, Sophie, Bruder-Costa, Juliana, Rome, Claire, Duley, Samuel, Hamaidia, Sieme, Betton, Patricia, Debernardi, Alexandra, Leroux, Dominique, Bernay, Benoit, Kieffer-Jaquinod, Sylvie, Combes, Florence, Ferri, Elena, McKenna, Charles E, Petosa, Carlo, Bruley, Christophe, Garin, Jérôme, Ferro, Myriam, Gressin, Rémy, Callanan, Mary B, Khochbin, Saadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944460/
https://www.ncbi.nlm.nih.gov/pubmed/23828858
http://dx.doi.org/10.1002/emmm.201202034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944460/
https://www.ncbi.nlm.nih.gov/pubmed/23828858
http://dx.doi.org/10.1002/emmm.201202034

Ejemplares similares